Match!

Switching from Premixed Insulin To Basal Insulin Analogue For Type 2 Diabetes and Role of Dipeptidyl Peptidase-4 Inhibitors

Published on Jul 13, 2017in Experimental and Clinical Endocrinology & Diabetes1.93
· DOI :10.1055/s-0043-113453
Fernando Gomez-Peralta8
Estimated H-index: 8
,
Cristina Abreu5
Estimated H-index: 5
+ 4 AuthorsMiguel Brito-Sanfiel2
Estimated H-index: 2
Abstract
Introduction This study aimed to confirm the usefulness of basal insulin analogue plus oral antidiabetic drugs (OADs) for type 2 diabetes (T2D) patients inadequately controlled with premixed insulin with/without OADs and assess the role of dipeptidyl peptidase-4 (DPP-4) inhibitors within this regimen in clinical practice. Methods Spanish retrospective observational study that included 186 T2D patients with glycosylated hemoglobin (HbA1c) >7% (53 mmol/mol) despite premixed insulin with/without OADs who had been switched to basal insulin analogue plus OADs. Study data describing the situation before the treatment switch and 6 months later was retrospectively retrieved from patients’ medical charts. Results Switching to a basal insulin plus OADs decreased HbA1c (−1.0%, p Conclusions Basal insulin analogue plus OADs may be a useful treatment for type 2 diabetes patients inadequately controlled with premixed insulin. Administering DPP-4 inhibitors within this regimen may contribute to improve patients’ glycemia, with a favorable weight-change profile and without increasing hypoglycemia risk.
  • References (31)
  • Citations (5)
References31
Newest
#1Ying Zhang (Guangzhou Medical University)H-Index: 2
#2Yi-juan Xie (Guangzhou Medical University)H-Index: 2
Last.En Liu (Guangzhou Medical University)H-Index: 2
view all 6 authors...
#1E. S. Hong (SNU: Seoul National University)H-Index: 1
#2A. R. Khang (SNU: Seoul National University)H-Index: 1
Last.Soo Lim (SNU: Seoul National University)H-Index: 42
view all 10 authors...
View next paperAdding Prandial Insulin to Basal Insulin Plus Oral Antidiabetic Drugs in Chinese Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Single-Arm Study